Organization
Tongji University
5 clinical trials
1 abstract
Clinical trial
A Single Arm, Single Center, Phase II Clinical Study of Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-02-25
Clinical trial
The Regulatory Function of Inhaled Asthma Medication Salbutamol on ThermogenesisStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Abstract
Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.Org: Tongji University, Nanchang,
Clinical trial
A Prospective, Multicenter, Double-blind, Randomized Controlled Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced NSCLCStatus: Not yet recruiting, Estimated PCD: 2025-11-22
Clinical trial
A Phase 1 Open-label, Single Arm Study Targeting Glypican-3 (GPC3) Chimeric Antigen Receptor Modified T Cells (CAR-T) for Treatment of Advanced Hepatocellular CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Neoadjuvant Sintilimab and Platinum-based Chemotherapy for Resectable Locally Advanced NSCLC Harboring no Driver Mutations: A Prospective, Randomized, Multicenter Phase III TrialStatus: Recruiting, Estimated PCD: 2024-10-31